
Our resources section is designed to be a toolkit supporting every step of your healthcare journey.
Achieving MDA or DAPSA treatment targets improves quality of life for patients with PsA.1–4 Explore the characteristics of patients who report treatment success...
ASDAS and BASDAI are commonly used in clinical practice.1,2 However, discover recent studies demonstrating that a high proportion of real-world patients do not...
Explore which treatment targets may be more appropriate for making treatment decisions in axSpA.
PsA and axSpA have overlapping disease manifestations which are driven by inflammation.1 Explore several extracellular cytokines that are implicated in these...
Watch Prof Frank Behrens discuss the importance of treating skin symptoms in addition to musculoskeletal symptoms for patients with SpA.
Achieving ACR50 is associated with improvements in quality of life for patients with PsA.1 Dive into the data supporting higher treatment targets in clinical...
EU-DA-2300319
Date of preparation: November 2023